Bjørn, M E2; de Stricker, K4; Kjær, L2; Ellemann, K3; Hasselbalch, H C2
1 Pathology, Department of Clinical Research, Det Sundhedsvidenskabelige Fakultet, SDU2 Hæmatologisk Afdeling, Roskilde Sygehus3 unknown4 Pathology, Department of Clinical Research, Det Sundhedsvidenskabelige Fakultet, SDU
Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera
We report a 55 year old woman with post-ET PV for 12 years, who experienced resolution of severe constitutional symptoms within 3 days, a marked reduction in splenomegaly and a rapid decline in the JAK2V617F allele burden during combination therapy with interferon-alpha2a and ruxolitinib. Within 4 weeks the patient achieved complete hematological remission with normalization of peripheral blood counts and within 10 months the JAK2V617F-allele burden was reduced from 90% to 28%. Such a rapid decline in the JAK2V617F allele burden is highly unusual in PV-patients during low-dose IFN-alpha2 monotherapy and this finding warrants a prospective study with combination therapy.
Leukemia Research Reports, 2014, Vol 3, Issue 2, p. 73-5